In this issue:
Mutagenic forces shaping the lung cancer genomes in never-smokers
Molecular determinants of sotorasib efficacy in KRAS G12C-mutated NSCLC
D3S-001 in KRAS G12C-mutated advanced solid tumours
Adagrasib vs. docetaxel in KRAS G12C-mutated NSCLC
Post-RT durvalumab in unresectable, chemotherapy-ineligible stage III NSCLC
Stereotactic radiosurgery in SCLC with 1–10 brain metastases
Selecting limited-stage SCLC patients for prophylactic cranial RT
Second primary cancers in lung cancer survivors by treatment type
Obrixtamig for DLL3+ SCLC or neuroendocrine carcinomas
Time toxicity of systemic anticancer therapies for metastatic lung cancer
Please login below to download this issue (PDF)